Standard BioTools Inc. expected to post a loss of 1 cent a share - Earnings Preview

Standard BioTools

04/08/2026 01:09

Standard BioTools Inc. LAB.OQ LAB.O is expected to  show a fall in quarterly revenue when it reports  results on August 5 for the period ending June 30 2026
The Boston Massachusetts-based  company is expected to report a 50.4% decrease in revenue to $20.805 million from $41.96 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Standard BioTools Inc. is for a loss of 1 cent per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Standard BioTools Inc. is $1.55, about 78.9% above its last closing price of $0.87
This summary was machine generated August 4 at 00:09 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)